The precise utility of positron emission tomography (PET) scanning for @entity5 is not well defined. We examined the trends of usage in a population-based data set. PET scans were performed in 3.60% of @entity1 with @entity150 , 1.09% of those with @entity263 , and 5.32% of those with @entity1358 . This selective usage might be driven by reimbursement constraints or identification of appropriate medical indications. INTRODUCTION: Positron emission tomography (PET) scanning is increasingly being used for imaging a variety of @entity5 , including @entity5 . The precise utility of PET scanning for @entity150 , @entity263 , and @entity1358 ( @entity1358 ) is not yet well known. We examined the trends in PET scan usage for 3 @entity5 using a large population-based data set. MATERIALS AND METHODS: We analyzed all individuals identified with a diagnosis of nonmetastatic @entity150 , @entity263 , and @entity1358 from the Surveillance, Epidemiology, and End Results-Medicare data set for 2004 to 2009 with follow-up data available to 2010. Logistic regression analysis and   (2) and trend tests were performed to determine the predictors of performing PET scanning. Separate models were run for each of the @entity5 diagnoses. All analyses were performed using SAS, version 9.3, and P < .05 was considered significant. RESULTS: We identified 20,865, 70,414, and 7007 @entity1 with a diagnosis of @entity150 , @entity263 , and @entity1358 , respectively, from 2004 to 2009. PET scans had been performed for 3.60% of @entity1 with @entity150 , 1.09% of those with @entity263 , and 5.32% of those with @entity1358 . On regression analysis, a more recent year of diagnosis, younger age, and high stage or grade were predictors of PET scan usage for @entity1 with @entity150 and @entity1358 . A higher Gleason score and higher D'Amico risk group predicted imaging with @entity263 . CONCLUSION: The usage of PET scanning for @entity150 , @entity263 , and @entity1358 is increasing but still very selective. The selective use might be driven by a combination of reimbursement constraints and careful identification of the appropriate medical indication.

Trends in PET Scan Usage for Imaging of @entity1 Diagnosed With Nonmetastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['urologic cancers', 'cancers', 'cancer'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']
@entity5 :: (MESH:D009369,Disease) :: ['Urologic Cancer']
